encodes several proteins, including a plasminogen activator [26] . In addition, unique plasminogen activator proteins have been described for S. pyogenes (streptokinase) and S. aureus (staphylokinase) [5, 6] . Unlike host plasminogen activators, neither streptokinase nor staphylokinase (SAK) possess enzymatic activity towards plasminogen and instead form 1:1 complexes with plasminogen that have both plasmin-like and plasminogen activator activity [27, 28] . An important distinguishing feature between these bacterial plasminogen activators is that SAK-plasminogen complexes are inhibited by az-antiplasmin, while streptokinase-plasminogen complexes cannot be inhibited in this manner [29, 30] .
Group A streptococci grown in human plasma can acquire plasmin-like enzymatic activity [15, 16] . This pathway has an absolute requirement for two bacterial products, a fibrinogenbinding protein and the secreted plasminogen activator, streptokinase, in addition to two human plasma proteins, fibrinogen and plasminogen [17, 18] . This highly evolved interaction between the pathogen and the human host demonstrates the potential for the group A organism to acquire a host enzyme with broad substrate specificity that can be generated and remain active despite the presence of efficient host regulator proteins.
Previous studies using S. aureus have demonstrated that these organisms can express plasminogen receptors and that the bound human protein can be activated by the addition of exogenous tPA [9] . These studies focused on model experiments using purified human plasminogen and exogenous tPA [9] and did not consider a potential role for SAK. The goal of the present study was to investigate if SAK-producing S. aureus isolates could utilize host proteins to acquire an unregulated surface plasmin-like activity.
Materials and Methods
Reagents. Urokinase (130-260 Plough U/Ji,L) and streptokinase (4000 World Health Organization [WHO] U/mg) were obtained from Sigma (St. Louis). tPA (-580 IU/J.Lg), >98% single chain, was a gift from R. Lottenberg (University of Florida, no 1996; 173 (January) Gainesville). The synthetic substrate for plasmin, H-D-Val-LeuLys-paranitroanilide (S-2251), was purchased from Kabi Pharmacia (Franklin, OR). Ruman thrombin, plasminogen-free fibrinogen, and a2-antiplasmin were obtained from Calbiochem (La Jolla, CA). Fibrinogen was cleaved with cyanogen bromide (CNBr) essentially as described [31] . Normal human plasma was obtained from the American Red Cross (Toledo). Native human plasminogen (GIu-plasminogen) and plasminogen-depleted plasma were prepared by passage over a lysine-Sepharose column (Pharmacia, Piscataway, NJ) as described [32] . The activity of arantiplasmin in plasminogen-depleted plasma was~85% of that in normal plasma as measured using a functional inhibition assay [33] . Human serum was prepared from plasma or plasminogendepleted plasma by the addition of 0.5 National Institutes ofHealth (NIH) U/mL thrombin in a final concentration of 25 mM CaCho All sources of human serum or plasminogen-depleted serum were preabsorbed with S. aureus to remove any reactive fibrinopeptides that might have been generated during serum generation. All plasma and serum preparations used in this study were derived from a pool of three different donor units of fresh-frozen plasma.
Bacterialstrains. Other Detection ofsurface-associatedplasmin(ogen)-dependent enzymatic activity. Staphylococci were harvested by centrifugation, washed twice in PBS (10 mMNa2HP04, 0.14 MNaCl, pH 7.4), and resuspended in the same buffer at~10 9 cfu/mL. Bacteriumassociated enzymatic activity was detected as follows. Following appropriate pretreatment, bacteria were pelleted by centrifugation at 4°C, and the bacterial pellet was washed twice with ice-cold PBS. The pellet was then resuspended in PBS and placed on ice. The enzymatic activity associated with the bacteria was determined by incubating an aliquot of a bacterial suspension with the synthetic substrate S-2251 (400 J.LM) in 0.4 mL of PBS at 37°C for 30 min. After the bacterial cells were removed by centrifugation, the plasmin-like enzymatic activity was determined by measuring the absorbance of 100 J.LL of bacterium-free supernatant at 405 nm in a microplate reader (Bio-Kinetics Reader EL312; Bio-Tek Instruments, Winooski, VT). Under these assay conditions, cleavage of S-2251 by fluid-phase plasmin was linear up to an A 40S of at least 1.25. Fluid-phase plasmin activity was determined similarly, following removal of bacteria, by adding 200 J.LL of S-225l to 50 J.LL of supernatant and monitoring substrate cleavage as described above.
Polymerase chain reaction (peR) techniques. PCR primers for SAK were synthesized at the Medical College of Ohio by the solid-phase phosphoramidite method (model 391B synthesizer; Applied Biosystems, Foster City, CA) and corresponded to the 5' and 3' ends of the S-Phi-C SAK gene published by Sako and Tsuchida [35] . The forward and reverse primers contain BamHI and EcoRI restriction sites, respectively, to facilitate forced-cloning into the temperature-inducible expression vector, pJLA602 (Medac, Hamburg, Germany). The primer sequences are as follows: (forward) 5'-GGGGGGATCCCCATGCTCAAAAGAAGT-TTATTA-3' and (reverse) 5'-GGGGGGGAATTCTTATTTCTT-TTCTATAACAACC-3'. Genomic DNA was isolated from staphylococci using the method described for small-scale isolation of DNA from streptococci [36) . Production of recombinant SAK. The PCR-amplified SAK gene product from S. aureus Cowan was treated with proteinase K (Life Technologies GIBCO BRL, Bethesda, MD) as described [37] . Plasmid DNA was isolated from DH5a containing pJLA602, as described [38) . The PCR product and pJLA602 were digested with BamHI and £CoRi (Life Technologies) according to manufacturer's instructions. Digested DNA was resolved by agarose gel electrophoresis and purified from the gel (QIAEX gel extraction kit; Qiagen, Chatsworth, CA). Ligation was done using T4 DNA ligase (Life Technologies) according to manufacturer's instructions. CaCh competent DR5a was transformed with ligation products essentially as described in [38] . Transformants were identified by plating on Luria-Bertani (LB) agar supplemented with 50 J.Lg/ mL ampicillin. Possible transformants containing an insert were identified by a shift in plasmid size following alkali lysis of a colony toothpick sample and subsequent agarose gel electrophoresis as described [38] .
AnalysisofrecombinantSAK. Potential SAK gene-expressing transformants were inoculated into LB broth containing ampicillin, grown at 30°C to an A sso of O. 7 with constant agitation, and recombinant protein expression was induced by temperature shift to 42°C for 2 h. Cells were centrifuged, washed, resuspended to 10% wet wt/vol in PBS, and disrupted by sonication. SAK activity in bacterium-free sonicates was measured by the ability of samples to activate GIu-plasminogen. Following incubation of 25 J.LL of plasminogen (0.2 J.LM) and 25 J.LL of a bacterium-free sonicate at 37°C for 30 min, 200 J.LL of the chromogenic substrate, S-2251, was added (400 J.LM), and SAK activity was measured by substrate conversion at 405 nm after a 30-min incubation at 37°C. Sonicates from pJLA602-transformed DH5a contained no plasminogen activator activity, even after a 5-h incubation with plasminogen at 37°C. SAK was standardized for plasminogen activator activity by comparison with a reference standard preparation of streptokinase (containing 4000 WHO U/mL) assayed under identical conditions. Recombinant SAK was purified on carboxymethylcellulose as described [39] . Plasminogen activator activity was monitored using a casein-agarose overlay procedure [40) . The purified recombinant SAK displayed plasminogen activator activity associated with a single~16,500 M, protein, as expected, on the basis of a previous report [41] .
Assay offibrin-clot lysis. Fibrinolytic activity of staphylococcal-associated enzymatic activity was done using a fibrin plate JID 1996; 173 (January) assay [12] . Briefly, fresh-frozen human plasma was clotted in 6-well petri plates (3.5 em) by the addition of CaC1 2 (25 mM; final concentration), fibrinogen (100 ttg/mL), and thrombin (0.5 NIH U/ mL). Bacteria were incubated with purified plasminogen or serum, either alone or in the presence of exogenous recombinant SAK. The bacteria were washed and standardized for cell-associated enzymatic activity as determined by incubation with the synthetic substrate S-2251. Ten microliters of a suspension of bacteria alone or bacteria with associated enzymatic activity were placed directly onto either the fibrin plate or a 0.22 ttmpore-sized filter membrane (Millipore, Bedford, MA) placed between the bacteria and the fibrin plate. The plates were incubated at 37°C for 18 h, and the degree of clot lysis was scored by measuring the zone of clearing.
Results
Previous studies have demonstrated that the zymogen human Glu-plasminogen could bind directly to certain S. aureus isolates and be activated subsequently by addition of exogenous tPA [9] . However, a potential role for the staphylococcal plasminogen activator, SAK, in the acquisition of cell-surface plasmin-like enzymatic activity was not analyzed. In the initial experiments, the abilities of SAK, urokinase, and tPA to acti-
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vate plasminogen prebound to staphylococci were compared. Staphylococcal isolates were preincubated at a concentration of 10 9 cfu/mL with various concentrations of human Glu-plasminogen in a final volume of 0.5 mL of PBS on ice. The bacteria were pelleted by centrifugation and washed twice to remove unbound plasminogen. Aliquots of each organism were then incubated either with buffer alone or with excess tPA, urokinase, or recombinant SAK for 30 min at 3rC. The quantity of cell-associated plasmin-like enzymatic activity was determined by cleavage of the plasmin-selective synthetic substrate, S-2251, as described in Methods.
The results for 1 representative isolate, isolate 89, demonstrate that the addition of exogenous urokinase, tPA or recombinant SAK, could activate plasminogen bound to staphylococci (figure I). The level of acquired enzymatic activity was proportional to the concentration of plasminogen allowed to interact with the bacteria. A similar pattern of binding and activation was observed with all of the staphylococcal isolates tested. These results indicate that exogenously added plasminogen activators, including SAK, could mediate the acquisition of enzymatic activity on the surface of plasminogen-loaded staphylococci.
c=J SAK Activation of plasminogen bound to surface of staphylococci by addition of excess exogenous staphylokinase (SAK, 100 U), urokinase (UK, 500 Plough U), or tissue plasminogen activator(tPA, 2500 ill). S. aureus isolate 89 (10 9 cfu) was allowed to react with various concentrations of human plasminogenin PBS for 1 h on ice. After extensive washing,plasminogen activatorswere added to cells and incubated for 30 min at 37°C. Cell-associated enzymatic activity was quantified as described in Methods. NOTE. Isolates are defined as SAK-positive or-negative by presence or absence ofSAK gene amplified by polymerase chain reaction as described in Metbods.
*Ability ofisolates tosecrete plasminogen activator was analyzed by incubating 25 J.lL of supernatant from overnight Todd-Hewitt broth culture with Glu-plasminogen (0.2 jJM) for 30 min at 37°C. Generation of plasmin-like activity was measured as described in Methods. -t-, A.os values > 10 times background conversion ofGlu-plasminogen incubated inbroth alone; -, A 40s values <2 times background conversion ofsubstrate.
! Cell-associated enzymatic activity was measured after incubation ofbacteria for 6h inchemically defined medium containing 20 J.lg/mL Glu-plasminogen. Bacteria were then washed inPBS and incubated for 2 h at37°C witb S-2251 (400 J.lM) after which cell-associated enzymatic activity was quantified. Variation in enzymatic activity of replicate samples from same isolate was <5%. Observed variation among isolates intbeir ability to acquire enzymatic activity was reproducible from experiment toexperiment tested under identical conditions.
In the next series of experiments,the ability of staphylococci to produce and secrete the necessary concentrations of SAK to mediate this reaction was tested. In these studies, a panel of staphylococcal strains isolated from humans was analyzed for the ability to acquire enzymatic activity when grown in a chemically definedmedium or in a chemicallydefinedmedium containing 20 Itg/mL human Glu-plasminogen. The results presented in table I demonstrate that of the 16 isolates studied, 8 acquiredsignificant levels of cell-associatedplasmin-likeenzymatic activity.
Analysis of these staphylococcalisolates for the presence of an SAK gene by PCR techniques indicated that there was an absolute correlationbetween isolateshavingthis gene and those that acquired plasmin-like enzymatic activity when incubated in the presence of a source of human plasminogen ( Although staphylococci can acquire cell surface-associated plasmin-like enzymatic activity in the presence of exogenous plasminogen, it was of interest to determine if this phenomenon could occur in the presence of physiologic regulatory proteins, in particular lX2-antiplasmin, which can regulate both fluidphase plasmin activity and the activity of the plasminogen-SAK complex [30] .
In a series of preliminary studies, staphylococciwere grown in humanplasma;however,the productionof coagulantactivity by the staphylococci resulted in fibrin clot formationand subsequent aggregationof the bacteria. This made analysis of acquisition of enzymatic activity by bacteria technically complex. Consequently, a series of preliminary experiments were done in which exogenousrecombinant SAK was added and the ability of the staphylococci to acquire plasmin-like enzymatic activity in short-term cultures (30 min at 37°C) was measured. Parallel comparative studies were also done using serum or serum containingCNBr-splitproducts of fibrinogen. The inclusion of CNBr-cleaved fibrinogen split products was tested on the basis of earlier results that showed a potential role for these products in facilitatingthe occurrenceof SAK-dependent plasminogen activation in the presence of lX2-antiplasmin [42] .
The results of these studies, presented in figure 2 for isolate 89, demonstrate that SAK can mediate acquisitionof equivalent levels of a plasmin-like enzymatic activity in plasma, serum, or serum supplemented with fibrinogen cleavage products. No enzymatic activity was captured if the source of plasma or serum was first depleted of plasminogen. These results were representative of the results obtained with the other SAK-producing staphylococcal isolates identified in table I (data not shown).
The ability to use serum rather than plasma enabled the interaction between staphylococci and human proteins to be studied over an extended period without the technicalproblems associatedwith clot formation or the need to add an exogenous source of SAK. (For these studies, the serum source was preincubated with S. aureus to remove any residual fibrinogen or fibrinopeptide that might have bound to the bacterial cell surface. The results obtainedwith absorbed and unabsorbedserum were identical.) The results presented in figure 3 demonstrate that SAK-producing strains can acquireplasmin-likeenzymatic activity when grown in human serum; those strains producing no detectable SAK acquire little or no activity when grown under identical conditions. Enzymatic activity was demonstratedto be plasminogen-dependent by the failureofplasminogen-depleted serum to result in acquisition of plasmin-like activity by any of the strains tested. The quantity of plasmin-like enzymatic activity acquired by staphylococci grown in serum could be significantly enhanced by the addition of exogenous SAK, indicating that it was the limiting factor in acquiring activity under the assay conditions tested (data not shown).
The efficiency of SAK-mediated acquisition of cell-associated plasmin-like enzymatic activity in serum was compared with that mediated by the eukaryotic plasminogen activators, urokinase and tPA. The results of a representative experiment, using isolate 89, are shown in figure 4 . When tPA or urokinase were used as plasminogen activators, the bacteria failed to acquire significant cell-associated plasmin-like enzymatic activity unless this activity was also detected in the fluid phase. This result indicates that all of the functional Cl'rantiplasmin in the fluid phase had been exhausted. Only SAK was capable of mediating acquisition of cell-bound enzymatic activity without enzyme activity being detected in the fluid phase of the reaction mixture ( figure 4) .
If the concentration of SAK was increased, fluid-phase plasmin activity could be generated; however, this resulted in no appreciable increase in the cell-associated plasmin-like enzymatic activity (figure 4). These results suggest that SAK, in the presence of staphylococci, can act preferentially in a coupled system to facilitate acquisition of cell surface-associated enzymatic activity without first generating fluid-phase plasmin. This reaction occurred in a manner protected from regulation by Cl'rantiplasmin and other fluid-phase serum regulatory proteins. The resulting cell-associated enzyme activity was not inhibitable by Cl'2-antiplasmin but could be completely inhibited by the addition of 1 mM aprotinin, a low molecular weight plasminselective inhibitor (data not shown). Similar results were obtained when these studies were carried out substituting human plasma for serum (data not shown).
Taken together, these results suggest a highly evolved strategy that enables staphylococci to secrete a unique plasminogen activator, SAK, and capture a plasmin-like protease activity that is no longer regulated by its usual physiological inhibitor, Cl'rantiplasmin. Since Cl'2-antiplasmin is the major physiological plasmin inhibitor in vivo, these findings suggest that the resulting unregulated host derived enzymatic activity associated with the staphylococcal surface would be functionally active under physiological conditions. The inability of Cl'2-antiplasmin to regulate cell-bound enzymatic activity, as measured by cleavage of a low molecular weight synthetic substrate, raised the concern that the active site of the bound enzyme might not be accessible to large macromolecules, such as fibrin, which is a natural substrate for plasmin.
In the next series of studies, staphylococci with cell-bound enzymatic activity acquired by incubation with either human serum or plasminogen plus exogenous SAK were tested for their ability to lyse a preformed fibrin clot. In this assay, washed bacteria with surface enzymatic activity were added to a plasma clot and the zone of clearing was measured following 18 h incubation at 37°C. Control samples of bacteria alone or bacte- ria preincubated in plasminogen-depleted serum were also included. The results presented in table 2 demonstrate that bacterium-associated plasmin-like enzymatic activity could lead to clot lysis. To ensure that this activity was mediated by cellbound enzymatic activity and not mediated by active enzyme(s) that had dissociated from the bacterial surface, the experiment was repeated with the bacteria separated from the clot by a 0.22-p,m Millipore filter. Under these conditions, no lysis of the clot was observed by bacterial preparations with cell-associated plasmin-like enzymatic activity (table 2) .
Discussion
Recent studies from our laboratory have demonstrated a coupled system in which group A streptococci can capture a host plasmin-like enzymatic activity when grown in human plasma [15, 16] . This reaction requires both plasminogen and fibrinogen and requires that the bacteria produce streptokinase and express a surface fibrinogen-binding structure [15] [16] [17] [18] . This pathway can function despite the presence of active c¥2-antiplasmin in the culture medium [15] [16] [17] . The focus of this study was to determine whether S. aureus organisms that secreted the plasminogen activator, SAK, could acquire plasmin-like enzymatic activity when incubated in the presence of human serum or plasma proteins.
Previous studies have demonstrated that S. aureus isolates could bind human plasminogen, which could be subsequently activated after the addition of tPA [9] . In this study, we have confirmed these results and demonstrated that plasminogen activation on the staphylococcal cell surface can also be accomplished by addition of SAK. We have also demonstrated the acquisition of a bound plasmin-like enzymatic activity by SAKproducing S. aureus isolates grown in human serum or plasma. This activity was absolutely dependent on the ability of the bacteria to secrete SAK and on the presence of a source of plasminogen.
The cell-associated enzymatic activity was not regulated by c¥rantiplasmin and was found to be effective in solubilizing fibrin clots. The mechanism by which SAK mediates capture of enzymatic activity by S. aureus in human serum or plasma is complex. SAK mediates a reaction that can result in acquisition ofbacterial-associated enzymatic activity in the absence of fluid-phase plasmin activity (see figure 4) . This was in marked contrast to the reactions involving tPA or urokinase, which had an absolute requirement for a fluid-phase plasmin intermediate. These findings indicate that SAK mediates conversion of plasminogen to plasmin using a protected mechanism that avoids regulation of both the plasminogen activator itself and the resulting plasmin by c¥2-antiplasmin present in the reaction mixture.
These results suggest a mechanism by which SAK secreted by staphylococci can either capture plasminogen directly on the cell surface or bind plasminogen in the fluid phase that is then captured. The plasminogen is then activated on the cell ++ regulatory system have been described [48, 49] , and thus, expression of virulence factors would be expected to vary depending on the conditions prevailing at the site of the infection. The finding that all of the organisms used in this study retained both activities suggests that both characteristics may be important for different phases of the infectious process or may be linked in a yet to be identified fashion that is beneficial to the pathogen.
Acquisition of plasmin-like enzymatic activity may be a shared characteristic of many invasive organisms. The ability of many invasive human pathogens to produce their own plasminogen activators [22] [23] [24] or to utilize host plasminogenactivators in a manner sheltered from physiologic regulation [21] suggests that this characteristicmay be of importance in generating an invasivephenotype [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . The observationthat many human pathogens share a common mechanism(s) for interacting with the host fibrinolytic system offers a potential target for new antibacterial strategies. surface, where it remains. The cell-surface enzymatic activity is protected from the effect of the potent physiologic inhibitor a2-antiplasmin while retaining the ability to lyse fibrin clots.
This mechanism has many similarities to the capture of a plasmin-likeenzymatic activity by group A streptococcigrown in human plasma [15] [16] [17] [18] . However, in the staphylococcal system, unlike the streptococcal system, there was no requirement for fibrinogen or for any other human plasma protein cofactor other than plasminogen in the acquisition of cell-associated enzymatic activity.
The ability to demonstrate acquisition of enzymatic activity for S. aureus grown in human serum was fortuitous since all ofthe SAK-producing isolates studied also produced coagulase. This property has made it difficult to study the acquisition of a plasmin(ogen)-dependent enzymatic activity by S. aureus isolates grown in human plasma because of the generation of a clot. The independent ability of a single pathogen to interact with two key homeostatic systems, the clotting pathway and the fibrinolytic system, is intriguing.
In a highly evolved human pathogen, one might anticipate selection for virulence characteristics that promote selective interactions with the host. In general, it would be anticipated that if the ability to form a clot were beneficial as a mechanism to promote colonization or to elude the host defense systems, then the organism would not also display a phenotype with clot lytic potential. Conversely, if acquisition of fibrinolytic potential had an advantage for colonization or invasiveness, then the conservation of a clotting enzyme would seem unnecessary.
Currently, no evidence has been reported for differential regulation of staphylokinase and coagulase production by S. aureus. However,production of coagulase is known to be negatively regulated by the accessory gene regulator system (agr) [43, 44] . Agr positively regulates a series of genes that code for potential virulence factors that could contribute to S. aureus pathogenicity [45] [46] [47] . The effect of nutrients and pH on this
